CY9D Stock Overview A pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Microbot Medical Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Microbot Medical Historical stock prices Current Share Price US$1.85 52 Week High US$3.70 52 Week Low US$0.70 Beta 1.46 1 Month Change 95.98% 3 Month Change 112.13% 1 Year Change 47.14% 3 Year Change -66.71% 5 Year Change -82.34% Change since IPO -98.68%
Recent News & Updates Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $7.000002 million. Jan 09
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $8.600009 million. Jan 08
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $7.000002 million. Jan 07
New major risk - Share price stability Jan 04
Microbot Medical Inc. Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY Dec 30
Microbot Medical Inc. Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System Dec 11 See more updates Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $7.000002 million. Jan 09
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $8.600009 million. Jan 08
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $7.000002 million. Jan 07
New major risk - Share price stability Jan 04
Microbot Medical Inc. Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY Dec 30
Microbot Medical Inc. Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System Dec 11
New major risk - Financial position Nov 16
Microbot Medical Inc., Annual General Meeting, Dec 17, 2024 Nov 07
Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial Oct 15
Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market Oct 14
Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System Sep 17
Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center Jul 18
Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial Jul 08 Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million. Jul 02
Microbot Medical Inc. announced that it has received $1.762502 million in funding Jun 21
New major risk - Shareholder dilution Jun 06 Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million. Jun 06
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.
New major risk - Share price stability Jun 03
Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health Apr 30
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US Feb 06
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters Jan 30
New major risk - Shareholder dilution Jan 24
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study Jan 19
Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met Dec 29
Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study Dec 07
Microbot Medical Inc. Announces Executive Changes Nov 22
Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process Nov 15
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study Nov 01 Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company Oct 20
Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System Oct 18
Microbot Medical Inc., Annual General Meeting, Nov 02, 2023 Sep 06
Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board Aug 11
Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office Jun 23
New major risk - Shareholder dilution Jun 08
Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System Jun 03
LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process Jun 01
Microbot Medical Inc. announced delayed 10-Q filing May 17
Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System May 10
Microbot Medical Inc. Announces Final Data from Its Recent Animal Study May 06
Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization May 04
Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel Dec 10
Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance Nov 19
High number of new directors Nov 16
Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System Nov 04
Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board Nov 01
Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System Oct 19
Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System Oct 14
Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System Oct 12
Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop. Oct 08
Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment Oct 06
Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board Sep 20
Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board Sep 16
Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System Sep 13
Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board Sep 09
Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System Sep 07
Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month Sep 03
Microbot Medical Inc., Annual General Meeting, Sep 21, 2022 Aug 09
High number of new directors Apr 27
High number of new directors Apr 15
Microbot Medical Inc. Announces Executive Changes Apr 07
Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States Dec 24
Microbot Medical Inc. Secures Patent Allowance in China and Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology Jun 30
New 90-day high: €8.75 Feb 18
Microbot Medical Announces Successful Outcome of Its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt Jan 29
New 90-day high: €7.00 Jan 26
Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with Liberty Robotic System Jan 15
New 90-day low: €5.55 Dec 31
Microbot Medical Inc. Announces Successful Animal Study Utilizing Its Liberty™ Robotic System Sep 17
New 90-day low - €5.40 Sep 04
New 90-day high - €6.90 Aug 15 Shareholder Returns CY9D DE Medical Equipment DE Market 7D 69.0% 1.0% 1.7% 1Y 47.1% -8.3% 9.4%
See full shareholder returns
Return vs Market: CY9D exceeded the German Market which returned 9.4% over the past year.
Price Volatility Is CY9D's price volatile compared to industry and market? CY9D volatility CY9D Average Weekly Movement 31.9% Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CY9D's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CY9D's weekly volatility has increased from 19% to 32% over the past year.
About the Company Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
Show more Microbot Medical Inc. Fundamentals Summary How do Microbot Medical's earnings and revenue compare to its market cap? CY9D fundamental statistics Market cap €30.74m Earnings (TTM ) -€10.88m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CY9D income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$11.21m Earnings -US$11.20m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/09 01:35 End of Day Share Price 2025/01/09 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Microbot Medical Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raghuram Selvaraju H.C. Wainwright & Co. Jeffrey Cohen Ladenburg Thalmann & Company
Show 0 more analysts 
